The device is engineered to address degenerative disc disease via transforaminal lumbar interbody fusion techniques. Credit: ronstik / Shutterstock.

Amphix Bio has received a breakthrough device designation from the US Food and Drug Administration (FDA) for its drug-device combination product aimed at bone regeneration.

This designation specifically pertains to the treatment of degenerative disc disease through transforaminal lumbar interbody fusion (TLIF) procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Amphix Bio’s product has a mouldable material that allows for easy application by surgeons in various surgical contexts and complex anatomies.

The implant is designed to induce growth of the bone without the need for donor tissue or recombinant proteins. This advancement could present significant benefits over existing products for TLIF spinal surgeries.

It is claimed to be the first time that the FDA is evaluating a product based on supramolecular peptide amphiphiles, which is Amphix Bio’s foundational technology platform.

Amphix Bio co-founder and chief scientific officer Samuel Stupp said: “This designation from the FDA is a major milestone for supramolecular therapeutics, and validates the high unmet need that our approach addresses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The expedited assessment and review are especially important given that we are aiming to advance an entirely new regenerative medicine platform to the clinic.”

The breakthrough programme aims to expedite the creation, evaluation and review process for medical devices or drug-device hybrids that promise to improve the treatment of life-impairing illnesses.

Amphix Bio is engaged in the development of a new class of regenerative medicine therapies.

The company also provides an off-the-shelf bone graft substitute that enables orthopaedic surgeons to perform spinal fusion surgeries without relying on donor tissue or recombinant proteins, which are commonly used in current methods.